Rozeman Leida B, Hogendoorn Pancras C W, Bovée Judith V M G
Department of Pathology, Leiden University Medical Center, P O Box 9600, NL-2300 RC Leiden, The Netherlands.
Expert Rev Mol Diagn. 2002 Sep;2(5):461-72. doi: 10.1586/14737159.2.5.461.
The mechanisms of chondrosarcoma development are just beginning to be unraveled. The distinction between benign and low-grade malignant cartilaginous tumors is difficult and is based mainly on radiological and clinicopathological features. In this review, the conventional chondrosarcomas are subdivided into central and secondary peripheral chondrosarcomas, based on their different genetic and clinicopathological background. Thus far, no diagnostic markers have been identified for central tumors. Bcl-2 is a good diagnostic marker that can be used in the distinction between osteochondroma and low-grade secondary peripheral chondrosarcoma. For the prognosis of chondrosarcomas, the best and most commonly used marker at present is histological grade. Several molecular markers, recapitulated in this paper, have been tested to see if they aid in determining diagnosis and predicting prognosis, but most are not independent of histological grade.
软骨肉瘤的发病机制才刚刚开始被揭示。良性和低度恶性软骨肿瘤之间的区分很困难,主要基于放射学和临床病理特征。在本综述中,传统软骨肉瘤根据其不同的遗传和临床病理背景分为中央型和继发性外周型软骨肉瘤。到目前为止,尚未发现中央型肿瘤的诊断标志物。Bcl-2是一种很好的诊断标志物,可用于区分骨软骨瘤和低度继发性外周型软骨肉瘤。对于软骨肉瘤的预后,目前最好且最常用的标志物是组织学分级。本文概述的几种分子标志物已进行测试,以确定它们是否有助于诊断和预测预后,但大多数并不独立于组织学分级。